Spots Global Cancer Trial Database for A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
Official Title: A Phase I Dose-finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors.
Study ID: NCT00921869
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally twice daily to patients with advanced solid tumors.
Detailed Description: Phase I, open-label, dose-escalation study to determine the maximum tolerated dose (MTD) of E7050 given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Kashiwa-shi, Chiba, Japan
Contact Details
Name: Takashi Sawada
Affiliation: Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
